Beyond the Biopsy: 3 Risk Factors That Make IBD-Related Dysplasia More Concerning (And What to Do)

Not every patient with inflammatory bowel disease (IBD) is at the same risk for dysplasia. Some low-grade dysplasia instances can be safely managed, while others may indicate a higher risk of developing cancer, particularly if other IBD dysplasia risk factors are present.

Improving long-term outcomes and reducing overall IBD-related colon cancer risk factors requires an understanding of these variations. The main characteristics of high-risk dysplasia IBD, the distinction between low-grade vs high-grade dysplasia IBD, and useful strategies for dysplasia management IBD will all be covered in this article.

Read More: Diet for Ulcerative Colitis: What to Eat and Avoid to Manage Flares Naturally

What Dysplasia Means in the Context of IBD

One of the most dreaded side effects of inflammatory bowel disease (IBD) is colorectal cancer (CRC). Long-term colon inflammation, a characteristic of both Crohn’s disease (CD) and ulcerative colitis (UC), can lead to genetic and epigenetic alterations that drive dysplasia, a neoplastic transformation.

Dysplastic lesions eventually develop into cancer if they are permitted to persist. Researchers commonly recognize that the degree and duration of inflammation mainly influence the risk of colorectal cancer.

The majority of risk factors, such as a family history of colon cancer, the presence of pseudopolyps, primary sclerosing cholangitis, and, of course, the severity and duration of the disease, cannot be changed, except for histological inflammation during colonoscopy.

Therefore, some of these unchangeable risk factors can be used to identify patients at risk and who should undergo screening and surveillance colonoscopies.

Why Some Dysplasia Findings Carry More Risk Than Others

Abnormal cells in a tissue or organ are called “dysplasia.” Although it is not cancer, it may progress to cancer and is sometimes called precancer. Additionally, several forms of developmental dysplasia can impact various body parts. Typical forms of dysplasia consist of:

The term “abnormal growth dysplasia” typically describes aberrant cell or tissue growth that can occasionally precede cancer:

Cervical Dysplasia: Low-grade cervical dysplasia usually resolves on its own without the need for therapy. Moreover, cervical cancer may result from high-grade cervical dysplasia.

Syndromes of Myelodysplastic: Impacts the bone marrow and can occasionally result in leukemia.

Developmental Dysplasia: Has an impact on a child’s growth but does not cause cancer.

Developmental dysplasia comes in various forms, such as:

• Hip dysplasia
• Skeletal dysplasia
• Ectodermal dysplasia affects skin, hair, nails, teeth, and sweat glands

Different dysplasias exhibit different behaviors. A diagnosis’s potential for worry depends on several criteria. Among them are:

• The lesion’s appearance (visible vs. invisible)
• How many different areas are involved?
• The patient’s entire medical history
• Conditions that coexist, including primary sclerosing cholangitis (PSC)

Risk Factor #1: Multifocal Dysplasia

What “Multifocal” Means

Dysplastic alterations in several colonic regions are referred to as multifocal dysplasia in IBD. The appearance of aberrant cells in several areas rather than a single isolated lesion indicates a broader process.

Why Multiple Areas Increase Concern

Multifocal dysplasia indicates that the colon has undergone significant alterations due to persistent inflammation. It increases the overall risk of IBD precancerous lesions because multiple sites have the potential to progress independently.

How It Changes Surveillance or Treatment Plans

When multifocal dysplasia is present, treatment frequently changes to include closer observation or possibly surgery. The threshold for intervention decreases, even if some cases of low-grade dysplasia may still be seen.

Read More: Ulcerative Colitis: Causes, Symptoms, and Treatment

What to Do If Multifocal Dysplasia Is Found

Clinicians typically advise a more proactive strategy when they discover multifocal dysplastic IBD:

Surgical Consultation: Any high-grade dysplasia (HGD) or multifocal low-grade dysplasia (LGD) often warrants colon excision.

Verify Pathology: Given the high morbidity rate, obtain a second opinion from a GI pathologist specializing in IBD to confirm the results.

Expert Endoscopy: To find any overlooked lesions or undetected malignancy, perform a second, high-quality surveillance colonoscopy employing dye-spray chromoendoscopy or high-definition imaging.

Clinicians still make decisions on an individual basis despite the elevated risk. Clinicians do not always recommend immediate surgery for all patients with high-risk dysplastic IBD, but they closely monitor them.

Risk Factor #2: Invisible or Flat Dysplasia

What Invisible Dysplasia Means

Compared to the general population, patients with inflammatory bowel disease (IBD) are more likely to acquire colorectal cancer. To increase early diagnosis of neoplasia and avoid colorectal cancer, patients with IBD are subjected to more frequent dysplasia surveillance.

Even though clinicians can detect most IBD-related dysplasia using modern high-definition (HD) scopes, random biopsies may still reveal some dysplasia known as “invisible dysplasia.”

Why Flat Lesions Are Harder to Monitor

A polyp is the precursor to colon cancer. Due to their mushroom-like shape, many polyps are simple to identify. However, the flat ones are more lethal and are readily overlooked during a colonoscopy, particularly if the colon is not clear. To properly and thoroughly remove these tiny flat lesions, a unique procedure known as endoscopic mucosal resection is also necessary.

One extremely delicate colonoscopic procedure is endoscopic mucosal resection. Clinicians first inject fluid carefully into the colon wall beneath the lesion to lift the flat lesion. They then carefully remove the lesion and the outer layers of the colon without damaging the deeper layers.

Challenges With Ongoing Surveillance

Surveillance relies on sophisticated imaging and random biopsies because invisible dysplasia is difficult to target. It raises the likelihood of overlooking problematic areas, which raises the IBD dysplasia risk factors.

What to Do If Dysplasia Is Not Clearly Visible

Due to high interobserver variability, endoscopically invisible dysplasia identified in random samples should be validated by a pathologist with experience in IBD; most guidelines recommend confirmation by a second experienced pathologist.

Follow-up should include referrals to IBD surveillance specialists for chromoendoscopy and high-definition colonoscopy. Based on the features of the lesion, resection and additional surveillance rather than proctocolectomy should be advised if visible lesions are found during a repeat colonoscopy with chromoendoscopy (see the previous discussion).

Clinicians should repeat random biopsies if no lesions are found. Because individuals with invisible LGD have a higher likelihood of later developing HGD/CRC, clinicians should weigh the advantages and disadvantages of proctocolectomy versus ongoing short-interval surveillance when they discover LGD incidentally.

Risk Factor #3: Coexisting Primary Sclerosing Cholangitis (PSC)

How PSC Changes Colorectal Cancer Risk

One well-known risk factor for colorectal cancer (CRC) is inflammatory bowel disease (IBD). IBD contributes to up to one-third of deaths in patients with ulcerative colitis, while CRC complicates IBD in only 1%–2% of cases.

PSC is a long-term condition with no recognized cause. In PSC, inflammation and fibrosis destroy and stenose intrahepatic and extrahepatic biliary ducts, leading to cholestasis. Portal tract fibrosis and biliary cirrhosis may appear as the illness worsens, which could eventually result in hepatic cirrhosis, failure, and death.

In addition to colorectal cancer, PSC increases the risk of cholangiocarcinoma, pancreatic carcinoma, gallbladder cancer, hepatocellular carcinoma, and other hepatobiliary cancers. PSC may be becoming more common, perhaps due to earlier detection and a rising suspicion index.

The typical survival time from PSC diagnosis to death or liver transplantation is roughly 12 years, with a mean age of 40 years.

Why Surveillance Often Starts Earlier

Colonoscopy surveillance usually begins earlier and is more frequent due to the increased risk of dysplasia in patients with primary sclerosing cholangitis. Close observation is necessary even for patients in remission or with modest symptoms.

Increased Frequency of Screening

Clinicians frequently advise people with PSC to undergo annual colonoscopy because they fall into a high-risk dysplastic IBD category.

Read More: Crohn’s and Colitis: Facts, Symptoms, and Support Tips

What to Do If You Have Both IBD and PSC

A progressive cholestatic, inflammatory, and fibrotic condition, primary sclerosing cholangitis (PSC) is closely linked to inflammatory bowel disease (IBD). Patients with PSC-IBD are at a higher risk of developing malignancies such as colorectal cancer and cholangiocarcinoma. PSC-IBD is a distinct disease entity.

Nevertheless, no effective medical treatment significantly improves the prognosis of PSC, even as disease features develop. Patients with PSC-IBD have the same therapeutic options as those with PSC alone.

Based on the pathophysiology of PSC-IBD, potential candidate medications have been identified, including those that target inflammation, fibrosis, gut dysbiosis, and bile acid regulation.

The following surveillance program is advised for PSC/IBD patients:

• Yearly gallbladder cancer ultrasound examination.
• Clinicians image the biliary tree every 6 to 12 months using MRI, MRCP, or ultrasound and measure blood levels of the tumor marker carbohydrate antigen (CA) 19-9 to detect signs of CCA.
• Every three to five years, PSC patients without concurrent IBD should get a surveillance colonoscopy. Every one to two years after the diagnosis of PSC, individuals with coexisting IBD should have a surveillance colonoscopy.
• Hepatocellular carcinoma screening is necessary for PSC patients with cirrhosis.

Other Factors That May Influence Risk

Several other factors influence IBD dysplasia risk factors in addition to the three main ones:

• Long duration of ulcerative colitis or Crohn’s colitis
• Chronic inflammation
• Dysplasia in the past
• Colorectal cancer runs in the family

How Doctors Decide Between Monitoring and Treatment

Surveillance Colonoscopy Strategy

The predicted progression of low-grade to high-grade dysplasia and ultimately to invasive carcinoma is not always followed by IBD-related colorectal cancer (CRC), in contrast to sporadic CRC. It is likely because the genetic events shared by both illnesses occur at different frequencies and sequences.

Patients with colonic disease for 8–10 years or more should be monitored annually, every 3 years, or every 5 years, depending on the presence of other risk factors.

Endoscopic Removal When Possible

It is frequently possible to eliminate dysplasia endoscopically if it is evident and localized. By lowering IBD colon cancer risk factors, this strategy protects the colon.

When Surgery May Be Discussed

Endoscopic resection should be considered for any clearly defined dysplastic-appearing lesion without significant submucosal fibrosis or stigmata of invasive malignancy. Clinicians advise referral to an IBD center or specialist endoscopist if they are uncertain about a lesion’s resectability.

If they discover invisible dysplasia, a skilled endoscopist should repeat the examination using high-definition dye-spray chromoendoscopy under ideal viewing conditions. If they see no lesion, they should perform extensive non-targeted biopsies in the area of the previous abnormality.

Surgeons should perform colectomy if histology reveals unresectable visible dysplasia or unseen multifocal or high-grade dysplasia. Clinicians continue endoscopic surveillance at regular intervals for visible lesions that can be removed or when a high-quality dye-spray chromoendoscopy examination does not confirm histologic abnormalities.

Read More: Can Lung Cancer Be Silent? What “No Symptoms” Really Means

Questions to Ask After a Dysplasia Diagnosis

Patients should take an active role in their care after receiving a dysplasia diagnosis. Important queries consist of:

• Do I have obvious or undetectable dysplasia?
• Are there several areas at play?
• How frequently should surveillance take place?
• Do I need to get a second opinion?
• What are my dysplasia management IBD options?

Signs That Warrant Prompt Medical Follow-Up

Even while dysplasia may not create symptoms in and of itself, some alterations should be taken seriously by a doctor:

• Rectal hemorrhage, either new or increased.
• Persistent symptoms despite therapy.
• Clinicians observe unexplained weight loss.
• New pain in the abdomen.

These symptoms are not unique to cancer, but they may point to alterations in the risk of IBD precancerous lesions and call for assessment.

Read More: Diet and Lifestyle Tips After a Pancreatic Cancer Diagnosis

Conclusion

Dysplasia in inflammatory bowel disease is a complex phenomenon that extends beyond a biopsy report and requires careful understanding. As we have seen, not every case is equally concerning, and different risk profiles can lead to very different outcomes for individuals.

Factors such as lesion distribution, visibility, and associated circumstances significantly impact clinical decisions. Early detection and regular monitoring often support effective risk management and better long-term results.

Close cooperation between patients and healthcare providers ensures that decisions about monitoring or treatment are made on time and appropriately. Knowing when closer observation or intervention is needed can help a lot in stopping the spread of more serious diseases.